GSK’s Phase III Meningococcal Vaccine Results Heat Up Race with Pfizer
BIOMARKER
1. GSK's next-gen meningococcal vaccine shows safe and effective results in Phase III trial for protecting against disease caused by serogroups A, B, C, W, and Y.
2. The vaccine combines strains from Bexsero and Menveo, which are currently licensed in the U.S.
3. The vaccine is designed for healthy adolescents and adults aged 10-25 years old, with a single injection.
4. Bexsero is intended for infants and young children, while Menveo protects against serogroups A, C, W and Y in teens and adults.
5. The Phase III data shows statistical non-inferiority compared to Bexsero and Menveo in healthy individuals 10–25 years old.
6. GSK's vaccine has the potential to provide broad protection against meningococcal disease, which is most common in infants, young children, and adolescents.
7. The vaccine was well-tolerated by study participants, and no serious adverse events were reported.
8. The data from the ESPID meeting provides further support for the development of the GSK meningococcal ABCWY vaccine, currently in Phase III clinical trial.
9. Pfizer's candidate looms as the FDA's October decision date approaches for its investigational pentavalent meningococcal vaccine candidate.
10. GSK is committed to bringing the vaccine to patients as soon as possible, pending regulatory approval.